Trials / Completed
CompletedNCT00859053
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the effects of hepatic impairment on the single dose pharmacokinetics of BMS-790052.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-790052 | Capsules, Oral, 30 mg, single dose, one day |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-03-10
- Last updated
- 2015-10-08
- Results posted
- 2015-10-08
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00859053. Inclusion in this directory is not an endorsement.